Log In
BCIQ
Print this Print this
 

APG-1252

  Manage Alerts
Collapse Summary General Information
Company Ascentage Pharma Group Corp. Ltd.
DescriptionSecond generation BCL-2/Bcl-XL inhibitor
Molecular Target B cell lymphoma 2 (BCL-2) (BCL2) ; Bcl-XL
Mechanism of ActionBcl-2 inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today